|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Ilorasertib
Description of
Ilorasertib (ABT-348):
Ilorasertib, also know as
ABT-348, is a novel,
potent and orally bioavailable inhibitor of the Aurora kinases as
well as the VEGF and PDGF families of receptor tyrosine kinases and
is currently in Phase I clinical trials.
ABT-348 has
nanomolar potency (IC50) for inhibiting binding and cellular auto-phosphorylation
of Aurora B (7 and 13 nM), C (1 and 13 nM) and A (120 and 189 nM).
Based upon its unique spectrum of activity,
ABT 348 was
evaluated and found effective in representative solid tumor (HT1080
and MiaPaCa, tumor stasis) and hematological malignancy (RS4;11,
regression) xenografts. These results provide the rationale for
clinical assessment of
ABT-348 as
a therapeutic agent in the treatment of cancer.
Current developer: Abbott Laboratories, Inc.
|
MedKoo Code#:
204140
|
|
Name:
Ilorasertib
|
|
CAS#:
1227939-82-3
Synonym: ABT-348;
Abbott 968660; Ilorasertib
IUPAC/Chemical name:
1-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea
|
|
Chemical structure
|
Theoretical analysis
|
|
-chemical%20structure.gif)
|
MedKoo Code#: 204140
Name: Ilorasertib
CAS#: 1227939-82-3
Chemical Formula: C25H21FN6O2S
Exact Mass: 488.14307
Molecular Weight: 488.54
Elemental Analysis: C, 61.46; H, 4.33; F, 3.89; N, 17.20; O,
6.55; S, 6.56
|
|
Availability and price:
Ilorasertib (ABT-348)
is
available through custom synthesis.
Minimum order is
requested.
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Highlights of recent research using this agent
|
1: Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J,
Reuter DR, Tapang P, Wei RQ,
Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM,
Bouska JJ,
Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert
DH.
Preclinical characterization of ABT-348, a kinase inhibitor targeting
the Aurora,
VEGFR/PDGFR, and SRC kinase families. J Pharmacol Exp Ther. 2012 Aug 30.
[Epub
ahead of print] PubMed PMID: 22935731.
2: Curtin ML, Heyman HR, Frey RR, Marcotte PA, Glaser KB, Jankowski JR,
Magoc TJ,
Albert DH, Olson AM, Reuter DR, Bouska JJ, Montgomery DA, Palma JP,
Donawho CK,
Stewart KD, Tse C, Michaelides MR. Pyrazole diaminopyrimidines as dual
inhibitors
of KDR and Aurora B kinases. Bioorg Med Chem Lett. 2012 Jul
15;22(14):4750-5.
Epub 2012 May 26. PubMed PMID: 22695126.
3: Curtin ML, Frey RR, Heyman HR, Soni NB, Marcotte PA, Pease LJ, Glaser
KB,
Magoc TJ, Tapang P, Albert DH, Osterling DJ, Olson AM, Bouska JJ, Guan
Z,
Preusser LC, Polakowski JS, Stewart KD, Tse C, Davidsen SK, Michaelides
MR.
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase
families.
Bioorg Med Chem Lett. 2012 May 1;22(9):3208-12. doi:
10.1016/j.bmcl.2012.03.035.
Epub 2012 Mar 14. PubMed PMID: 22465635.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
